Cargando…

Incidence and Predictors of Sars-Cov-2 Antibody Responses Following COVID-19 Vaccination in Allogeneic Stem Cell Transplant Recipients

Background Pharmacologic immunosuppression and incomplete immune reconstitution after allogeneic stem cell transplant (alloSCT) may impair a patient's ability to mount an immune response to vaccines, including currently available COVID-19 vaccines. Since immunocompromised patients are susceptib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Minehart, Janna C., Catania, Christopher, Perry, Linda, Martin, Mary Ellen, Smith, Jacqueline, McCurdy, Shannon R., Pratz, Keith W., Luger, Selina M., Timlin, Colleen, Perl, Alexander E., Schuster, Mindy, Porter, David L, Loren, Alison W., Hexner, Elizabeth O., Frey, Noelle V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology. Published by Elsevier Inc. 2021
Materias:	722.Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701570/ http://dx.doi.org/10.1182/blood-2021-153920

Ejemplares similares

Antibody Response to Sars-Cov-2 Vaccination in Patients Following Allogeneic Hematopoietic Cell Transplantation
por: Cicin-Sain, Caroline, et al.
Publicado: (2021)

Sars-Cov-2 T-Cell Response in Allogeneic Hematopoietic Stem Cell Recipients Following Two Doses of BNT162b2 Vaccine
por: Clemenceau, Beatrice, et al.
Publicado: (2021)

Interest of a Third Dose of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Stem-Cells Recipients
por: Le Bourgeois, Amandine, et al.
Publicado: (2021)

Chronic Graft-Versus-Host Disease (cGVHD) Exacerbation after Sars-Cov-2 Covid Vaccination
por: Trunk, Andrew D., et al.
Publicado: (2021)

Antibody Response to 2-Dose Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Cell Transplant Recipients
por: Maillard, Alexis, et al.
Publicado: (2021)

Humoral and T Cell Immune Responses to Sars-Cov-2 Vaccination in Hematopoietic Cell Transplant Recipients
por: Gavriilaki, Eleni, et al.
Publicado: (2021)

Low Frequency of T Cell and Antibody Responses to Vaccination Against Sars-Cov-2 in Patients Post Allogeneic Stem Cell Transplantation in Comparison with Chronic Myeloid Malignancy Patients
por: Harrington, Patrick, et al.
Publicado: (2021)

Profound B-Cell Lymphopenia Is a Major Factor Predicting Poor Humoral Response after BNT162b2 mRNA Sars-Cov-2 Vaccines in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
por: Jullien, Maxime, et al.
Publicado: (2021)

Serological Response Following BNT162b2 Anti-Sars-Cov-2 mRNA Vaccination in Hematopoietic Stem Cell Transplantation Patients
por: Attolico, Imma, et al.
Publicado: (2021)

Humoral Serologic Response to the BNT162b2 Vaccine Afterallogeneic Haematopoietic Cell Transplantation
por: Yeshurun, Moshe, et al.
Publicado: (2021)

Timing and Immune Status after Cellular Therapies Predict Response to COVID-19 Vaccines
por: Tamari, Roni, et al.
Publicado: (2021)

COVID-19 Vaccination after Allogeneic Stem Cell Transplantation: Real Word Data on Safety and Efficacy. a Single Center Experience.
por: Neagoie, Adela, et al.
Publicado: (2021)

Response to BNT162b2 Sars-Cov-2 Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
por: Saraceni, Francesco, et al.
Publicado: (2021)

Identification of Respiratory Viral Infection in Hematopoietic Stem Cell Transplant Recipients - Impact on Non Relapse Mortality
por: Imlay-Gillespie, Louise, et al.
Publicado: (2015)

Sars-Cov-2 Infection and Vaccination in Recipients of Reduced-Intensity Conditioning, Posttransplantation Cyclophosphamide (PTCy)-Based Allogeneic Hematopoietic Cell Transplantation (HCT)
por: Dimitrova, Dimana, et al.
Publicado: (2022)

Putative Protective Role of Sars-Cov-2-Specific T Cells in an HCT Patient Transplanted during Active COVID19 Infection
por: Pourhassan, Hoda, et al.
Publicado: (2022)

Efficacy of a Third Sars-Cov-2 Vaccine Dose in Allogeneic Hemopoietic Cell Recipients: a Systematic Review and Meta-Analysis
por: Rubin, Micah, et al.
Publicado: (2023)

Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies
por: Cichocki, Frank, et al.
Publicado: (2023)

Allogeneic natural killer cell therapy
por: Berrien-Elliott, Melissa M., et al.
Publicado: (2023)

Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies
por: Quach, David H., et al.
Publicado: (2023)

Genome-edited allogeneic donor “universal” chimeric antigen receptor T cells
por: Qasim, Waseem
Publicado: (2023)

COVID-19 in Pediatric Hematopoietic Cell Transplant Recipients: A CIBMTR Study
por: Bhatt, Neel S., et al.
Publicado: (2021)

COVID-19 in Children Following Hematopoietic Cell Transplantation: A Multinational Study of the European Bone Marrow Transplantation Society (EBMT) and the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH)
por: Averbuch, Diana, et al.
Publicado: (2021)

Allogeneic and Autologous Hematopoietic Transplants Can be Safely Performed after COVID-19 Infections
por: Ramdial, Jeremy L., et al.
Publicado: (2021)

COVID-19 Infection of HSCT Recipients Is Associated with High Mortality but No Detectable Cytokine Storm at Presentation
por: Lucchini, Giovanna, et al.
Publicado: (2021)

Risk Factors for Severe Form of COVID-19 after Allogeneic Hematopoietic Stem Cell Transplantation: A SFGM-TC Multicentre Cohort Study
por: Xhaard, Alienor, et al.
Publicado: (2020)

COVID-19 and Stem Cell Transplantation; Results from the Prospective Survey By the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT) and the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH)
por: Ljungman, Per, et al.
Publicado: (2020)

Clinical Characteristics and Outcomes of COVID-19 in HSCT Recipients
por: Machado, Clarisse MARTINS, et al.
Publicado: (2020)

Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
por: Matthews, Andrew H., et al.
Publicado: (2022)

Conversion from tacrolimus to belatacept improves renal function in kidney transplant patients with chronic vascular lesions in allograft biopsy
por: Pérez-Sáez, María José, et al.
Publicado: (2018)

Implication of interleukin-2 receptor antibody induction therapy in standard risk renal transplant in the tacrolimus era: a meta-analysis
por: Ali, Hatem, et al.
Publicado: (2019)

Dose intensity for induction in acute myeloid leukemia: what, when, and for whom?
por: McCurdy, Shannon R., et al.
Publicado: (2021)

Inflammatory Cytokine Inhibition with Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease
por: Rager, Alison, et al.
Publicado: (2010)

Abstract 2193: Synthesis of the Transmembrane Domain of the Spike Protein from SARS-CoV-2 Using Solid Phase Peptide Synthesis and Determination of Its Oligomerization State
por: Grimes, Loyal, et al.
Publicado: (2023)

Abstract 2189: The Impact of N-butyldeoxynojirimycin and 1-deoxymannojirimycin on SARS-CoV-2 S1 Subunit and Angiotensin-Converting Enzyme 2 Interaction in Intestinal Epithelial Cells
por: El Khoury, Marianne, et al.
Publicado: (2023)

Abstract 2702: Highly synergistic combinations of nanobodies that target SARS-CoV-2 reduce viral load in hACE2 transgenic mice
por: Olivier, Paul, et al.
Publicado: (2023)

Abstract 2610: Modifications in SARS-CoV-2 N Linker Region Regulate RNA Interactions and Phase Separation
por: Shah, Sahana, et al.
Publicado: (2023)

Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD
por: Akahoshi, Yu, et al.
Publicado: (2023)

Graft versus host disease after liver transplantation: A case report
por: Acar, Sencan, et al.
Publicado: (2022)

Postinflammatory hyperpigmentation after human cold pain testing
por: Wolz, Melissa J., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5gph987kt3s2nainm36cqjbaql